Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAvalon Allergen Testing Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedAvalon Healthcare SolutionsPolicy AHS - G2031 - Allergen Testing

    Allergen Testing

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - G2031 - Allergen Testing alerts

    Get alerted when Policy AHS - G2031 - Allergen Testing changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of serum and other allergen-testing services, including specific and total IgE testing, for Avalon Healthcare Solutions members. Coverage depends on the member’s benefit plan and applicable government policies, which control if they conflict with this policy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyAllergen Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 2026
    Last ReviewOct 16, 2025
    Next Review DateN/A
    Key ActionBefore allergy testing, obtain an allergy-focused clinical history and select testing based on the history, safety, and provider competency.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage was added for annual retesting to monitor allergy resolution.

    Routine retesting criteria were revised.

    The documentation requirement for selecting in-vitro testing instead of skin testing was removed.

    The procedure-code set was updated.

    Noncovered allergy-testing criteria were consolidated to support clearer enforcement.

    1Annual retesting exception for children and adolescents with positive food allergen results
    1Routine-retesting scenario that does not meet coverage criteria
    3Codes added in this revision
    1Code removed in this revision
    2Former allergy-testing criteria consolidated

    Covered and Noncovered Allergy Testing

    Specific IgE in-vitro testing

    Specific IgE in-vitro allergy testing is covered when all of the following are met.

    Specific IgE testing: The allergens are selected based on the individual's history, physical examination, and environment, and testing is limited to no more than 20 allergen-specific antibodies per year.Up to 20 allergen-specific antibodies per year

    Total serum IgE testing

    Total serum IgE testing is covered when any of the following situations applies.

    Qualifying indications

    • Moderate to severe asthma: The individual has moderate to severe asthma.
    • Allergic bronchopulmonary aspergillosis: The individual has signs or symptoms of allergic bronchopulmonary aspergillosis.

    Pediatric food-allergen retesting

    Annual repeat testing is covered when all of the following are met.

    Monitoring food allergy resolution: The individual is a child or adolescent with an initial positive food-allergen result, and annual retesting is performed for the same food allergen or allergens to monitor for allergy resolution.Annual retesting; same food allergen(s)

    General testing principles

    Testing selection and interpretation should be clinically directed.

    Clinically directed allergen selection: Select allergens based on the patient's age, history, examination, environment, living conditions, occupation, activities, geographic region, and suspected exposure; interpret results in the context of the clinical history and findings.

    Skin testing should ideally use relevant, standardized extracts.

    Clinical indications for allergen testing

    Testing may be useful when clinical features suggest allergic disease.

    Relevant clinical indications: Testing may be considered for asthma; rhinitis, rhinosinusitis, rhinoconjunctivitis, or conjunctivitis; selected eczema or atopic dermatitis with high suspicion for IgE hypersensitivity; suspected food, drug, venom, or occupational allergy; systemic reactions after insect stings; and selected eosinophilic or allergic bronchopulmonary disorders.

    Utility may be controversial for some less common disorders.

    Choice of testing modality

    Use serum-specific IgE rather than skin testing when special clinical circumstances make skin testing unsafe or impractical.

    Circumstances favoring serum-specific IgE: Consider a specific-IgE immunoassay when the patient has widespread skin disease, is receiving skin-test-suppressive therapy, is uncooperative, or has a history suggesting unusually high risk of anaphylaxis from skin testing.

    Blood testing is an alternative when skin testing is not safe or useful.

    Food allergy

    For suspected IgE-mediated food allergy, testing is an adjunct to clinical assessment.

    Targeted food-allergy evaluation: Use skin-prick testing and/or serum-specific-IgE testing as diagnostic aids when food allergy is suspected; focus testing on foods suspected of provoking the reaction; and interpret results together with signs, symptoms, and likely or known exposure.

    Test results alone are not diagnostic of food allergy.

    Peanut allergy

    Peanut testing is appropriate when pretest probability is clinically judged to be high or moderate before oral food challenge.

    Peanut diagnostic testing: Use diagnostic skin-prick testing or serum-specific IgE for patients with physician-judged high pretest probability of peanut allergy, or perform testing before an oral food challenge in patients with moderate pretest probability. Ara h 2 may be used when a single diagnostic test is selected; skin-prick testing or whole-peanut serum-specific IgE may be used in high-probability cases.

    Routine addition of component testing to skin-prick testing or whole-peanut serum-specific IgE is not recommended, and these tests should not be used to predict future reaction severity.

    Rhinitis and contact dermatitis

    Testing should be targeted to the suspected condition.

    Rhinitis evaluation: For rhinitis symptoms, complete a detailed history and physical examination, review medications for drug-induced rhinitis, and use aeroallergen skin-prick testing or serum-specific IgE to confirm allergic rhinitis when clinically appropriate.

    Routine food skin-prick testing or food serum-specific IgE testing is not recommended for rhinitis symptoms.

    Contact dermatitis evaluation: Consider allergic contact dermatitis in chronic eczematous or noneczematous dermatitis and use patch testing to confirm suspected allergic contact dermatitis; evaluate relevant personal, home, workplace, cosmetic, clothing, footwear, and topical-product exposures.

    Patch testing is described as the diagnostic gold standard for suspected allergic contact dermatitis.

    Pediatric suspected IgE-mediated food allergy

    For children and young people under 19 years with suspected IgE-mediated food allergy:

    History-directed pediatric food-allergy testing

    • Initial test modality: Offer a skin-prick test and/or blood test for specific IgE antibodies to the suspected foods and likely co-allergens.

      Choose between modalities based on the history, safety, acceptability, and provider competency.

    • Safety and performance requirements: Testing must be selected, performed, and interpreted by appropriately competent healthcare professionals; skin-prick testing requires facilities capable of managing anaphylaxis.

    Peanut-specific testing before introduction

    For peanut-allergy prevention in high-risk infants:

    Peanut evaluation before introduction

    • High-risk infant evaluation: For an infant with severe eczema, egg allergy, or both, strongly consider evaluation with peanut-specific IgE measurement and/or skin-prick testing and, if necessary, an oral food challenge before introducing peanut-containing foods.4–6 months for peanut introduction in highest-risk infants

      Testing is strongly advised before peanut introduction.

    • Other high-risk setting: Strongly consider peanut-specific IgE measurement, skin-prick testing, or both before peanut introduction to determine whether peanut should be introduced and the preferred method of introduction.

      Peanut-specific IgE may be the preferred initial approach where skin-prick testing is not routine.

    Allergic rhinitis testing

    For suspected allergic rhinitis:

    Diagnostic confirmation or treatment planning: Use history and physical examination as the foundation; confirm with diagnostic testing when proceeding to allergen immunotherapy or targeted avoidance therapy, or when treatment response is inadequate.

    Skin-prick testing or serum allergen-specific IgE are appropriate diagnostic modalities; serum testing is an alternative when skin testing cannot be performed.

    Annual Retesting in Children and Adolescents

    Annual retesting meets coverage criteria when all specified conditions are met.

    Annual retesting for food allergy resolution: The individual has positive food-allergen results, is a child or adolescent, and is receiving annual retesting for the same food allergens to monitor for allergy resolution.Annual retesting

    This is the specified exception to the routine-retesting limitation.

    Routine Retesting Without New Clinical Presentation

    Routine retesting does not meet coverage criteria unless the annual retesting exception applies.

    Routine repeat testing limitation: The requested testing is routine retesting for the same allergens and there is no new clinical presentation.No new clinical presentation

    This does not meet coverage criteria, except for annual retesting in children and adolescents with positive food-allergen results.

    Specific IgE In-vitro Testing

    Specific IgE in-vitro allergy testing meets coverage criteria in specified situations.

    Specific IgE in-vitro testing indications: Specific IgE in-vitro allergy testing is performed in lieu of skin testing for an initial allergy screen; when skin testing is contraindicated; or when further treatment decisions would be impacted by confirmation of sensitivity in an individual whose direct skin-testing results are not consistent with the history of anaphylaxis or another severe reaction to an allergen.

    Annual Repeat Food Allergen Testing

    Annual retesting for the same food allergens meets coverage criteria in children and adolescents with positive food-allergen results.

    Annual repeat food-allergen testing: The individual is a child or adolescent, prior food-allergen results are positive, and annual retesting is performed for the same food allergens to monitor for allergy resolution.Annual retesting

    This is an exception to the general restriction on repeat testing for the same allergens.

    Basophil Activation and Immunoglobulin Testing

    For individuals with signs or symptoms of allergies, specified testing does not meet coverage criteria.

    Noncovered testing for allergy symptoms: The requested service is basophil activation flow cytometry testing or in-vitro testing of IgG, IgA, IgM, and/or IgD.

    Routine retesting for the same allergens does not meet coverage criteria when there is no new clinical presentation. The exception is annual retesting of the same food allergen or allergens in a child or adolescent with an initially positive food-allergen result, when performed to monitor for allergy resolution.

    The antigen leukocyte antibody test (ALCAT) does not meet coverage criteria.

    For individuals with signs or symptoms of allergies, basophil activation flow cytometry testing and in-vitro testing of IgG, IgA, IgM, and/or IgD do not meet coverage criteria.

    In-vitro allergen testing using bead-based epitope assays, including VeriMAP Peanut Dx, does not meet coverage criteria.

    Qualitative specific-IgE multi-allergen screens that do not identify a specific allergen do not meet coverage criteria in any situation.

    IgG and IgG-subclass antibody testing for food allergy does not meet coverage criteria because it lacks clinical relevance, validation, and sufficient quality control.

    Routine total serum IgE testing does not meet coverage criteria as a screening test for allergic disease, for predicting allergic disease, or as a routine diagnostic test for food allergy.

    Indiscriminate batteries of IgE tests and other unproven diagnostic tests should not be used in allergy evaluation. Testing should be directed toward suspected allergens and interpreted with the clinical presentation.

    Routine skin or serum-specific-IgE testing for inhalants or foods does not meet coverage criteria in chronic urticaria unless the history clearly implicates an allergen as a provoking or perpetuating factor.

    Skin-prick testing (SPT) is not routinely indicated for suspected food intolerance or nonspecific food-associated symptoms when other allergic features are absent.

    SPT is not routinely indicated to evaluate the effectiveness of allergen immunotherapy. It may provide supportive information during Hymenoptera venom immunotherapy.

    Absent other allergic features, SPT is not routinely indicated for chronic urticaria, nonspecific irritant-related respiratory symptoms, asymptomatic sensitization screening, nonspecific nonatopic rashes, weight-loss evaluation, nonspecific reactions to food additives or preservatives, migraine except selected suspected hormone hypersensitivity, or chronic fatigue syndrome.

    Routine food-allergy evaluation should not use total serum IgE as a diagnostic test or routinely combine skin-prick testing, serum-specific IgE, and atopy patch testing.

    Nonstandardized testing does not meet coverage criteria for routine food-allergy evaluation, including allergen-specific IgG, basophil histamine-release or activation, lymphocyte-stimulation, cytotoxicity, and mediator-release assays.

    Atopy patch testing and oral food challenges should not be used to diagnose IgE-mediated food allergy in primary care or community settings.

    Routine multiplex allergen testing, including ImmunoCAP ISAC, does not meet coverage criteria because evidence is insufficient for routine use to diagnose difficult-to-diagnose allergy or predict reaction risk.

    Routine retesting for the same allergens does not meet coverage criteria when there is no new clinical presentation. The exception is annual retesting of the same food allergens in children and adolescents with positive food-allergen results to monitor for allergy resolution.

    For individuals with signs or symptoms of allergies, basophil activation flow cytometry testing and in-vitro testing of IgG, IgA, IgM, and/or IgD do not meet coverage criteria.

    Allergen testing is not routinely indicated for asymptomatic screening or nonspecific symptoms without a compatible allergic history, including nonspecific food-associated symptoms, irritant-related respiratory symptoms, nonspecific rashes, or chronic urticaria without allergic features.

    Fractional exhaled nitric oxide (FeNO) or nasal nitric oxide testing should not be routinely used to diagnose allergic rhinitis. History and physical examination, diagnostic skin testing, or serum-specific IgE testing are first-line evaluation methods.

    Nasal histology does not meet coverage criteria for routine allergic-rhinitis evaluation because obtaining the specimen is invasive.

    Procedure Codes and Coding Guidance

    Applicable CPT/HCPCS Procedure CodesCPT
    82784Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each.
    82785Gammaglobulin (immunoglobulin); IgE.
    83516Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
    86001Allergen specific IgG quantitative or semiquantitative, each allergen.
    86003Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each.
    86005Allergen specific IgE; qualitative, multiallergen screen (eg, disk, sponge, card).
    86008Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each.
    88184Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker.
    88185Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker.
    Additional Codes Added in Revision HistoryCPT
    0165UProcedure code listed as added in the revision history; description not provided in this document window.
    0178UProcedure code listed as added in the revision history; description not provided in this document window.
    Proprietary Testsmixed
    VeriMAP Peanut DxPeanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy; proprietary test by AllerGenis Clinical Laboratory.
    VeriMAP Peanut SensitivityPeanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction; proprietary test by AllerGenis Clinical Laboratory.
    Removed CPT CodesCPTNot Covered
    83520CPT code removed from the policy
    Added CPT and Proprietary Codesmixed
    88185CPT code added to the policy
    0165UCPT code added to the policy
    0178UCPT code added to the policy
    Allergen-specific IgE testing
    Annual limitUp to 20 allergen-specific antibodies per year
    Testing methodIn-vitro specific IgE allergy testing
    Selection basisAllergens selected according to the individual's history, physical examination, and environment
    Food-allergy follow-up retesting
    Follow-up timingRoughly yearly re-evaluations may be considered during childhood
    Allergens commonly reassessed

    Documentation and Testing Safeguards

    Documentation Required

    History-Directed Testing

    Base testing on an allergy-focused clinical history before ordering allergy tests. Use the history to identify the suspected allergen(s), relevant exposures, timing, symptoms, and reaction pattern.

    Documentation Required

    Document Clinical Rationale

    Document the clinical history, physical examination, environmental or occupational exposures, and the supporting rationale for each requested test. Specific IgE testing should be limited to allergens selected from this patient-specific assessment.

    Documentation Required

    Patient-Specific Test Selection

    Select tests for the patient's presentation and interpret results using the clinical history, examination findings, relevant exposures, and local allergens. Do not rely on a test result without documenting how it informs diagnosis or management.

    Clinical Background

    Allergic disease commonly involves type I IgE-mediated reactions or type IV T-cell-mediated reactions. A positive serum allergen-specific IgE result confirms the presence of allergen-specific antibody, but does not by itself establish clinical reactivity. Clinical reactivity must be assessed using the patient's history or a supervised challenge. Skin or serum testing may help identify clinically relevant allergens, while patch testing is preferred for delayed T-cell-mediated responses.

    Allergy Testing Terms

    sIgE
    AbbreviationsIgE
    Full termSpecific immunoglobulin E
    Clinical useRefers to allergen-specific IgE measurement used to identify sensitization
    tIgE
    AbbreviationtIgE
    Full termTotal immunoglobulin E
    Coverage indicationsIn-vitro total serum IgE testing may meet coverage criteria for moderate to severe asthma or signs or symptoms of allergic bronchopulmonary aspergillosis
    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyAllergen Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 2026
    Last ReviewOct 16, 2025
    Next Review DateN/A
    Key ActionBefore allergy testing, obtain an allergy-focused clinical history and select testing based on the history, safety, and provider competency.
    SourceLink
    On This Page
    Covered and Noncovered Allergy TestingProcedure Codes and Coding GuidanceDocumentation and Testing SafeguardsClinical BackgroundAllergy Testing Terms
    Milk, egg, wheat, and soy
    Less frequent retestingMay be appropriate when results remain particularly high, such as >20-50 kUA/L
    Seasonal allergen panel size
    Tree allergens8 allergens identify ≥98% of sensitized patients within the tree class
    Weed and grass allergens5 weed allergens and 3 grass allergens identify ≥98% of sensitized patients within their respective classes
    Mold allergens7 mold allergens identify ≥98% of sensitized patients within the mold class
    Combined seasonal panelA minimum of 23 antigens is required to optimally detect sensitization across the four seasonal classes
    Peanut basophil activation severity marker
    MarkerCD63 peanut/anti-IgE ratio
    Threshold≥1.3
    Associated findingIncreased risk of severe reactions; relative risk 3.4
    Peanut basophil sensitivity marker
    MarkerBasophil allergen threshold sensitivity (CD-sens)
    Threshold≥84
    Associated findingIncreased risk of reacting to 0.1 g or less of peanut protein; relative risk 1.9
    Documentation Required

    Allergy-Focused History

    Record the suspected trigger, clinical presentation, timing of symptoms, exposure history, and other context needed to interpret the result. Allergy testing must not be performed without first obtaining an allergy-focused history.

    Documentation Required

    Qualified Personnel and Safety Capability

    Ensure testing is performed and interpreted by healthcare professionals with appropriate competency. Skin-prick testing must be performed only where facilities and personnel are available to manage an anaphylactic reaction.

    Documentation Required

    Rationale for Serum-Specific IgE

    When serum-specific IgE is used instead of skin testing, document the clinical reason skin testing is unsuitable, unsafe, or not acceptable and why serum testing will affect diagnosis or management.

    • Examples include extensive dermatitis or dermatographism, inability to discontinue antihistamines or other skin-test-suppressive therapy, an uncooperative patient, or an unusually high risk of anaphylaxis from skin testing.
    • Choose serum-specific IgE based on the history, test safety and acceptability, and the available competency to perform and interpret the test.
    Denial Risk

    Repeat Testing Without a New Presentation

    Routine retesting for the same allergen does not meet coverage criteria when there is no new clinical presentation.

    • Exception: annual retesting of the same positive food allergen(s) in children and adolescents may meet coverage criteria when performed to monitor resolution of food allergy.
    Denial Risk

    ALCAT Testing Not Covered

    ALCAT testing does not meet coverage criteria.

    Denial Risk

    Uncovered Antibody and Basophil Activation Testing

    The specified antibody and basophil activation modalities do not meet coverage criteria because published evidence does not establish that they are required and beneficial for diagnosis and treatment.

    • Basophil activation flow cytometry testing.
    • In-vitro testing of IgG, IgA, IgM, and/or IgD.
    Denial Risk

    Bead-Based Epitope Assays

    In-vitro allergen testing using bead-based epitope assays does not meet coverage criteria.

    • Examples include VeriMAP Peanut Dx and VeriMAP Peanut Sensitivity assays.
    • These emerging assays require additional peer-reviewed evidence establishing analytical validity, clinical validity, and clinical utility.
    Denial Risk

    Non-Specific Multi-Allergen Screens

    Qualitative specific-IgE multi-allergen screens that do not identify a specific allergen do not meet coverage criteria.

    Denial Risk

    Testing Without a Compatible Allergic Presentation

    Do not order allergy testing for asymptomatic patients or for symptoms without a compatible allergic presentation. Testing is not routinely indicated for nonspecific symptoms or conditions without supporting allergic features.

    • Examples include suspected food intolerance, nonspecific food-associated symptoms, nonspecific respiratory symptoms caused by irritants, screening based only on family history, nonspecific rashes without atopic features, migraine, and chronic fatigue syndrome.
    • Testing is also not routinely indicated solely to evaluate weight loss approaches, response to allergen immunotherapy, or chronic urticaria without allergic features.
    Denial Risk

    Indiscriminate Food or Panel Testing

    Avoid indiscriminate food or broad food-panel testing. Select suspected foods and likely co-allergens based on the allergy-focused history and clinical presentation.

    • Food panels and testing for foods unrelated to the suspected reaction can produce misleading results, overdiagnosis, and unnecessary dietary restrictions.
    • Positive serum-specific IgE or skin-prick results indicate sensitization and are not, by themselves, diagnostic of food allergy.
    Denial Risk

    Nonstandardized Allergy Testing

    Nonstandardized or nonvalidated allergy assays do not meet coverage criteria and should not be used for routine allergy evaluation.

    • Examples include basophil histamine release or activation assays, lymphocyte stimulation tests, allergen-specific IgG testing, cytotoxicity assays, and mediator-release assays.
    • Use standardized allergen extracts and validated skin or serum-specific-IgE methods when clinically indicated.
    Documentation Required

    Interpret Results in Clinical Context

    Do not use an allergy test result as a stand-alone diagnosis. Interpret sensitization results in the context of the patient's allergy-focused history, examination, exposure, and reaction pattern.

    • Specific IgE identifies sensitization and does not alone predict the probability, severity, or clinical relevance of an allergic reaction.
    • Treatment decisions should be based on history and, when appropriate, directed serum-specific IgE or skin-prick testing.
    Denial Risk

    Non-First-Line Rhinitis Evaluation

    For suspected allergic rhinitis, history and physical examination, followed when indicated by diagnostic skin testing or serum-specific IgE, are first-line evaluation methods.

    • Routine imaging is not recommended for diagnosing allergic rhinitis; nasal endoscopy may be used as a diagnostic adjunct in selected patients.
    • FeNO and nasal nitric oxide may provide additional information when necessary but should not be routinely used for allergic-rhinitis diagnosis because evidence is inconsistent and no agreed diagnostic cutoff exists.
    Documentation Required

    Sensitization Is Not Clinical Allergy

    Do not equate sensitization with clinical allergy. A positive specific-IgE result is a marker of allergic sensitization and must be correlated with the patient's symptoms and exposure history.

    • Specific IgE alone cannot predict whether a reaction will occur or how severe it will be.
    • Higher specific-IgE concentrations may correlate with increased risk in some settings, but the clinical diagnosis remains patient-specific.
    Denial Risk

    Noncovered Allergy Testing Modalities

    Basophil activation testing and in-vitro testing for immunoglobulins other than the covered specific-IgE methods do not meet coverage criteria.

    • Excluded modalities include basophil activation testing and testing for IgG, IgA, IgM, and/or IgD.
    • Do not substitute these modalities for clinically indicated skin testing or serum-specific IgE testing.
    Denial Risk

    Same-Allergen Retesting Exclusion

    Do not repeat testing for the same allergen without a new clinical presentation. Routine same-allergen retesting does not meet coverage criteria except for the specified annual food-allergen exception.

    • Annual retesting may meet coverage criteria for children and adolescents with an initial positive food-allergen result when monitoring for allergy resolution.
    BAT
    AbbreviationBAT
    Full termBasophil activation flow cytometry testing
    Alternate nameBasophil activation test
    ALCAT
    AbbreviationALCAT
    Full termAntigen Leukocyte Antibody Test
    Coverage statusDoes not meet coverage criteria
    BBEA
    AbbreviationBBEA
    Full termPeanut bead-based epitope assay
    Coverage statusIn-vitro allergen testing using bead-based epitope assays does not meet coverage criteria
    SPT
    AbbreviationSPT
    Full termSkin prick tests
    PurposeTests for allergen-specific IgE through skin exposure
    OFC
    AbbreviationOFC
    Full termOral food challenge
    Use in peanut evaluationTesting is recommended before an OFC for patients with moderate pretest probability of peanut allergy
    Skin-prick testing
    Test typeIn-vivo allergen-specific IgE testing
    TechniqueAllergen is introduced into the skin, most commonly by prick or puncture
    InterpretationResults must be interpreted with the medical history, clinical findings, and relevant allergens
    Specific IgE
    Test typeIn-vitro allergen-specific antibody measurement
    TargetAntibodies directed against a particular allergen
    Clinical limitationResults alone should not be considered diagnostic of food allergy
    Basophil activation test
    Test typeFunctional assay
    MeasurementBasophil activation or mediator release after exposure to an allergen
    Peanut study findingBAT showed dose-dependent upregulation of CD63 and CD203c in peanut-allergic children
    Allergic contact dermatitis
    ConditionAllergic contact dermatitis
    Diagnostic methodPatch testing
    RolePatch testing is described as the diagnostic gold standard for suspected allergic contact dermatitis
    Sensitization
    DefinitionPresence of allergen-specific antibodies indicating immune sensitization or risk for allergy
    Clinical meaningSensitization alone is not equivalent to clinical allergy
    Interpretive limitationSensitization does not independently predict an allergic reaction or its severity
    Serum allergen-specific IgE
    SpecimenBlood serum
    MeasurementAllergen-specific immunoglobulin E
    When usedMay be used when skin prick testing is not feasible or safe, including extensive dermatitis or inability to discontinue antihistamines
    Skin prick test
    Test typeSkin test for allergen-specific IgE
    MethodAllergen extract is introduced into the skin
    Practical featureGenerally a rapid method for testing multiple antigens
    Component-resolved or molecular allergy testing
    Testing approachUses allergen molecules or components
    PurposeRefines assessment of sensitization, reaction risk, or unknown triggers in selected patients
    Specialist useMay be an option for diagnosis in selected scenarios, including polysensitized patients
    Laboratory-developed test
    AbbreviationLDT
    Development and validationDeveloped, validated, and performed in-house by a laboratory
    Regulatory descriptionRegulated by CMS as a high-complexity test under CLIA '88; not FDA-approved or cleared
    Laboratory-developed test
    DefinitionA test developed, validated, and performed in-house by a laboratory
    CMS classificationRegulated by CMS as a high-complexity test under the Clinical Laboratory Improvement Amendments of 1988
    FDA statusFDA clearance or approval is not currently required for clinical use